Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bluejay Diagnostics (BJDX) Common Equity (2020 - 2026)

Bluejay Diagnostics' Common Equity history spans 3 years, with the latest figure at $2.9 million for Q4 2023.

  • On a quarterly basis, Common Equity fell 74.92% to $2.9 million in Q4 2023 year-over-year; TTM through Dec 2023 was $2.9 million, a 74.92% decrease, with the full-year FY2023 number at $2.9 million, down 74.92% from a year prior.
  • Common Equity hit $2.9 million in Q4 2023 for Bluejay Diagnostics, down from $5.2 million in the prior quarter.
  • Over the last five years, Common Equity for BJDX hit a ceiling of $20.4 million in Q4 2021 and a floor of $2.9 million in Q4 2023.
  • Historically, Common Equity has averaged $11.6 million across 3 years, with a median of $11.5 million in 2022.
  • Biggest five-year swings in Common Equity: tumbled 43.37% in 2022 and later plummeted 74.92% in 2023.
  • Tracing BJDX's Common Equity over 3 years: stood at $20.4 million in 2021, then tumbled by 43.37% to $11.5 million in 2022, then plummeted by 74.92% to $2.9 million in 2023.
  • Business Quant data shows Common Equity for BJDX at $2.9 million in Q4 2023, $5.2 million in Q3 2023, and $6.4 million in Q2 2023.